Ionis Pharmaceuticals Inc (IONS): Stanley T Crooke , Chairman and CEO of Ionis Pharmaceuticals Inc sold 11,000 shares on Apr 6, 2016. The Insider selling transaction was disclosed on Apr 7, 2016 to the Securities and Exchange Commission. The shares were sold at $46.12 per share for a total value of $507,375.00.
Currently the company Insiders own 1.6% of Ionis Pharmaceuticals Inc shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -2.83%.Institutional Investors own 84.71% of Ionis Pharmaceuticals Inc shares.During last six month period, the net percent change held by insiders has seen a change of -2.83%.
Ionis Pharmaceuticals Inc. formerly Isis Pharmaceuticals Inc. is a ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused on discovering and developing antisense drugs. Its antisense drugs are used to treat a range of diseases including cardiovascular; metabolic; severe and rare diseases including neurological disorders and cancer. Volanesorsen is a drug indicated to treat patients with high triglyceride levels including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. It is focused on bringing its late-stage Phase III drugs nusinersen volanesorsen and IONIS-TTR to the market. Its lipid-lowering product KYNAMRO (mipomersen sodium) injection is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). Its products also include Alicaforsen IONIS-DMPK-2.5 Plazomicin and IONIS-GCGR.